Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma.

about

Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.

P2860

Q47679443-33F17FB1-B286-44E2-889A-54325998DA07

P2860

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma.

Item

http://www.wikidata.org/entity/Q38722312

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Changes in uninvolved immunogl ...... ly diagnosed multiple myeloma.

@en

type

Item

label

Changes in uninvolved immunogl ...... ly diagnosed multiple myeloma.

@en

prefLabel

Changes in uninvolved immunogl ...... ly diagnosed multiple myeloma.

@en

P1476

Changes in uninvolved immunogl ...... ly diagnosed multiple myeloma.

@en

P2093

A Dispenzieri

http://www.w3.org/2001/XMLSchema#string

D Dingli

http://www.w3.org/2001/XMLSchema#string

F Buadi

http://www.w3.org/2001/XMLSchema#string

J A Lust

http://www.w3.org/2001/XMLSchema#string

M A Gertz

http://www.w3.org/2001/XMLSchema#string

M Q Lacy

http://www.w3.org/2001/XMLSchema#string

P Kapoor

http://www.w3.org/2001/XMLSchema#string

P L Bergsagel

http://www.w3.org/2001/XMLSchema#string

P Ravi

http://www.w3.org/2001/XMLSchema#string

R A Kyle

http://www.w3.org/2001/XMLSchema#string

P2860

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

International uniform response criteria for multiple myeloma.

Review of 1027 patients with newly diagnosed multiple myeloma.

Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

P2888

bcj.2017.46

P304

e569

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BCJ.2017.46

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nelson Leung

S. Vincent Rajkumar

Shaji K Kumar

P577

2017-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1086039648

http://www.w3.org/2001/XMLSchema#string

P698

28622306

http://www.w3.org/2001/XMLSchema#string

P932

5584483

http://www.w3.org/2001/XMLSchema#string

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma.

about

P2860

P2860

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932